How much funding has nChroma Bio raised?

nChroma Bio has raised $335.0M in total funding, most recently a Corporate Round.

Who are nChroma Bio's investors?

nChroma Bio's investors include GV (Google Ventures), Flagship Pioneering, ARCH Venture Partners, Sofina.

When was nChroma Bio founded?

nChroma Bio was founded in 2024.

Where is nChroma Bio headquartered?

nChroma Bio is headquartered in Boston, Massachusetts, United States.

What industry is nChroma Bio in?

nChroma Bio operates in Biotech, Genomics, Life Sciences, Therapeutics.

How many employees does nChroma Bio have?

nChroma Bio has 51-200 employees.

nChroma Bio

nChroma

Boston, United States · Founded 2024 · $335.0M raised

Headquarters: Boston, Massachusetts
Employees: 51–200
Founded: 2024
Business Model: B2B

Website: nchromabio.com
Total Funding: $335.0M
Last Round: $75.0M Corporate RoundDec 2024
Rounds: 3

About

nChroma Bio is a clinical-stage genetic medicines company developing targeted in vivo delivery systems and engineered epigenetic silencers for durable disease treatment. Its lead program, CRMA-1001, is a liver-directed epigenetic therapy in Phase 1/2 trials targeting a functional cure for chronic hepatitis B. The company combines lipid nanoparticle delivery with proprietary epigenetic editing to achieve durable gene silencing without altering the underlying DNA sequence.

Summary

nChroma Bio is a Biotech company based in Boston, United States, founded in 2024. It has raised $335.0M in total across 3 rounds, most recently a $75.0M Corporate Round round in Dec 2024. Investors include GV (Google Ventures), Flagship Pioneering and ARCH Venture Partners.

LinkedIn X (Twitter)